Table 4.

IOP lowering effects of topical cannabinoids.

Authors	Study Population	Intervention	Results
Merritt et al., 1981 [67]	6 hypertensive glaucoma patients	single 0.05% delta-9-THC eye drop	No significant IOP lowering
		single 0.1% delta-9-THC eye drop	No significant IOP lowering
Merritt et al., 1981 [68]	8 hypertensive glaucoma patients	single 0.01% delta-9-THC eye drop	No significant IOP lowering
		single 0.05% delta-9-THC eye drop	No significant IOP lowering
		single 0.1% delta-9-THC eye drop	No significant IOP lowering
Green et al., 1982 [69]	16 healthy subjects	single administration of 1% delta-9-THC eye drop	No significant IOP lowering
Jay et al., 1983 [70]	28 healthy subjects	1% delta-9-THC eye drop four times a day for a week	No significant IOP lowering
Porcella et al., 2001 [71]	8 glaucoma patients (4 POAG, 2 malformative glaucoma, 1 pigmentary glaucoma, 1 angle closure glaucoma)	25 µg of WIN55212-2, two drops	15 ± 0.5% IOP lowering after 30 min from administration
		50 µg of WIN55212-2, two drops	23 ± 0.9% IOP lowering after 30 min from administration
Pescosolido et al., 2018 [72]	5 glaucoma patients (4 POAG and 1 post-uveitic glaucoma)	Bediol (containing 3–6 mg/mL of delta-9-THC and 4–8 mg/mL of cannabidiol) twice a day for 30 days and then switched to topical Bedrocan (containing 18–23 mg/mL of delta-9-THC and 1.2–18 mg/mL of cannabidiol) twice a day for 30 days	No significant IOP lowering regardless of employed compound.

POAG: primary open angle glaucoma, IOP: intraocular pressure, THC: Tetrahydrocannabinol.